blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3536712

EP3536712 - METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  20.03.2026
Database last updated on 07.04.2026
FormerThe patent has been granted
Status updated on  28.04.2023
FormerGrant of patent is intended
Status updated on  13.03.2023
FormerExamination is in progress
Status updated on  17.12.2020
FormerRequest for examination was made
Status updated on  06.03.2020
FormerThe application has been published
Status updated on  09.08.2019
Most recent event   Tooltip20.03.2026Opposition rejectedpublished on 22.04.2026 [2026/17]
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6706 / US
[2023/22]
Former [2019/37]For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6706 / US
Inventor(s)01 / SWERGOLD, Gary
75 Sheldrake Place
New Rochelle, NY 10804 / US
 [2019/37]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2023/22]
Former [2019/37]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date19162319.812.09.2012
[2019/37]
Priority number, dateUS201161535392P16.09.2011         Original published format: US 201161535392 P
US201161559162P14.11.2011         Original published format: US 201161559162 P
US201261641321P02.05.2012         Original published format: US 201261641321 P
[2019/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3536712
Date:11.09.2019
Language:EN
[2019/37]
Type: B1 Patent specification 
No.:EP3536712
Date:31.05.2023
Language:EN
[2023/22]
Search report(s)(Supplementary) European search report - dispatched on:EP31.07.2019
ClassificationIPC:C07K16/40, A61P3/06, A61K39/00, A61P7/00, A61P9/00, A61P9/10, A61P11/00, A61P27/02, A61P43/00
[2023/14]
CPC:
C07K16/40 (EP,US); A61K39/3955 (US); A61P11/00 (EP);
A61P27/02 (EP); A61P3/06 (EP); A61P43/00 (EP);
A61P7/00 (EP); A61P9/00 (EP); A61P9/10 (EP);
A61K2039/505 (EP,US); C07K2317/21 (EP); C07K2317/76 (EP) (-)
Former IPC [2019/37]C07K16/40, A61P3/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/15]
Former [2019/37]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA02.03.2020
ME02.03.2020
TitleGerman:VERFAHREN ZUR REDUZIERUNG DES LIPOPROTEIN (A)-SPIEGELS DURCH VERABREICHUNG EINES INHIBITORS DER PROPROTEINKONVERTASE SUBTILISIN KEXIN-9 (PCSK9)[2019/37]
English:METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)[2019/37]
French:PROCÉDÉS POUR RÉDUIRE LES NIVEAUX DE LIPOPROTÉINE(A) PAR L'ADMINISTRATION D'UN INHIBITEUR DE LA PROPROTÉINE CONVERTASE SUBTILISINE KEXINE 9 (PCSK9)[2019/37]
Examination procedure02.03.2020Examination requested  [2020/15]
02.03.2020Date on which the examining division has become responsible
30.06.2020Amendment by applicant (claims and/or description)
24.09.2020Observations by third parties
16.12.2020Despatch of a communication from the examining division (Time limit: M06)
28.09.2021Reply to a communication from the examining division
23.12.2021Despatch of a communication from the examining division (Time limit: M06)
26.07.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
05.10.2022Reply to a communication from the examining division
25.01.2023Observations by third parties
21.03.2023Communication of intention to grant the patent
22.03.2023Fee for grant paid
22.03.2023Fee for publishing/printing paid
22.03.2023Receipt of the translation of the claim(s)
27.03.2023Observations by third parties
Parent application(s)   TooltipEP12761864.3  / EP2756004
Divisional application(s)EP23176223.8  / EP4252857
EP24202055.0  / EP4461373
Opposition(s)Opponent(s)01  29.02.2024  10.03.2026  WITHDRAWN
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
Opponent's representative
Bijvank, Koen Mattijs Lodewiek
Brinkhof N.V.
Grote Bickersstraat 74-78
1013 KS Amsterdam / NL
 [2026/16]
Former [2025/41]
Opponent(s)01  29.02.2024  01.03.2024  ADMISSIBLE
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
Opponent's representative
Bijvank, Koen Mattijs Lodewiek
Brinkhof N.V.
Grote Bickersstraat 74-78
1013 KS Amsterdam / NL
Former [2024/15]
Opponent(s)01  29.02.2024  01.03.2024  ADMISSIBLE
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
Opponent's representative
Dörries, Hans Ulrich
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
18.03.2024Invitation to proprietor to file observations on the notice of opposition
18.06.2024Reply of patent proprietor to notice(s) of opposition
11.03.2025Date of oral proceedings
24.04.2025Despatch of minutes of oral proceedings
24.04.2025Date of despatch of rejection of opposition
10.03.2026Legal effect of rejection of opposition [2026/17]
Appeal following opposition25.04.2025Appeal received No.  T0620/25
25.04.2025Payment of appeal fee
22.08.2025Statement of grounds filed
10.03.2026Result of appeal procedure: appeal of the opponent withdrawn
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
05.10.2022Request for further processing filed
05.10.2022Full payment received (date of receipt of payment)
Request granted
13.10.2022Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
28.09.2021Request for further processing filed
28.09.2021Full payment received (date of receipt of payment)
Request granted
11.10.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
30.06.2020Request for further processing filed
30.06.2020Full payment received (date of receipt of payment)
Request granted
10.07.2020Decision despatched
Fees paidRenewal fee
12.03.2019Renewal fee patent year 03
12.03.2019Renewal fee patent year 04
12.03.2019Renewal fee patent year 05
12.03.2019Renewal fee patent year 06
12.03.2019Renewal fee patent year 07
19.09.2019Renewal fee patent year 08
17.09.2020Renewal fee patent year 09
15.09.2021Renewal fee patent year 10
15.07.2022Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY12.09.2012
HU12.09.2012
AT31.05.2023
BG31.05.2023
CZ31.05.2023
DK31.05.2023
EE31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
MC31.05.2023
PL31.05.2023
RO31.05.2023
RS31.05.2023
SE31.05.2023
SI31.05.2023
SK31.05.2023
SM31.05.2023
TR31.05.2023
NO31.08.2023
GR01.09.2023
LU12.09.2023
IS30.09.2023
PT02.10.2023
[2026/04]
Former [2025/39]CY12.09.2012
HU12.09.2012
AT31.05.2023
BG31.05.2023
CZ31.05.2023
DK31.05.2023
EE31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
MC31.05.2023
PL31.05.2023
RO31.05.2023
RS31.05.2023
SE31.05.2023
SI31.05.2023
SK31.05.2023
SM31.05.2023
NO31.08.2023
GR01.09.2023
LU12.09.2023
IS30.09.2023
PT02.10.2023
Former [2025/36]CY12.09.2012
AT31.05.2023
BG31.05.2023
CZ31.05.2023
DK31.05.2023
EE31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
MC31.05.2023
PL31.05.2023
RO31.05.2023
RS31.05.2023
SE31.05.2023
SI31.05.2023
SK31.05.2023
SM31.05.2023
NO31.08.2023
GR01.09.2023
LU12.09.2023
IS30.09.2023
PT02.10.2023
Former [2024/51]AT31.05.2023
BG31.05.2023
CZ31.05.2023
DK31.05.2023
EE31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
MC31.05.2023
PL31.05.2023
RO31.05.2023
RS31.05.2023
SE31.05.2023
SI31.05.2023
SK31.05.2023
SM31.05.2023
NO31.08.2023
GR01.09.2023
LU12.09.2023
IS30.09.2023
PT02.10.2023
Former [2024/28]AT31.05.2023
CZ31.05.2023
DK31.05.2023
EE31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
MC31.05.2023
PL31.05.2023
RO31.05.2023
RS31.05.2023
SE31.05.2023
SI31.05.2023
SK31.05.2023
SM31.05.2023
NO31.08.2023
GR01.09.2023
LU12.09.2023
IS30.09.2023
PT02.10.2023
Former [2024/25]AT31.05.2023
CZ31.05.2023
DK31.05.2023
EE31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
PL31.05.2023
RO31.05.2023
RS31.05.2023
SE31.05.2023
SI31.05.2023
SK31.05.2023
SM31.05.2023
NO31.08.2023
GR01.09.2023
LU12.09.2023
IS30.09.2023
PT02.10.2023
Former [2024/10]AT31.05.2023
CZ31.05.2023
DK31.05.2023
EE31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
PL31.05.2023
RO31.05.2023
RS31.05.2023
SE31.05.2023
SK31.05.2023
SM31.05.2023
NO31.08.2023
GR01.09.2023
IS30.09.2023
PT02.10.2023
Former [2024/08]AT31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
PL31.05.2023
RS31.05.2023
SE31.05.2023
SK31.05.2023
SM31.05.2023
NO31.08.2023
GR01.09.2023
IS30.09.2023
Former [2024/03]AT31.05.2023
FI31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
PL31.05.2023
RS31.05.2023
SE31.05.2023
NO31.08.2023
GR01.09.2023
IS30.09.2023
Former [2024/01]AT31.05.2023
HR31.05.2023
LT31.05.2023
LV31.05.2023
PL31.05.2023
RS31.05.2023
SE31.05.2023
NO31.08.2023
GR01.09.2023
IS30.09.2023
Former [2023/51]AT31.05.2023
HR31.05.2023
PL31.05.2023
RS31.05.2023
SE31.05.2023
NO31.08.2023
GR01.09.2023
IS30.09.2023
Former [2023/50]AT31.05.2023
PL31.05.2023
SE31.05.2023
NO31.08.2023
GR01.09.2023
IS30.09.2023
Former [2023/48]AT31.05.2023
SE31.05.2023
NO31.08.2023
Documents cited:Search[Y] WO2011028938  (ALNYLAM PHARMACEUTICALS INC et al.)
 [A]   NORDESTGAARD BORGE G ET AL: "Lipoprotein(a) as a cardiovascular risk factor: current status", EUROPEAN HEART JOURNAL, vol. 31, no. 23, December 2010 (2010-12-01), pages 2844, XP002688211, ISSN: 0195-668X

DOI:   http://dx.doi.org/10.1093/EURHEARTJ/EHQ386
 [Y]   PARHOFER KLAUS G: "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", CURRENT PHARMACEUTICAL DESIGN, vol. 17, no. 9, March 2011 (2011-03-01), pages 871 - 876, XP002688212, ISSN: 1381-6128

DOI:   http://dx.doi.org/10.2174/138161211795428777
Examination  THOMAS DEMANT ET AL: "The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans", ATHEROSCLEROSIS, vol. 157, no. 2, 1 August 2001 (2001-08-01), pages 325 - 339, XP055215912, ISSN: 0021-9150, DOI: 10.1016/S0021-9150(00)00732-2

DOI:   http://dx.doi.org/10.1016/S0021-9150(00)00732-2
   GAUDET DANIEL ET AL: "Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, vol. 114, no. 5, 18 June 2014 (2014-06-18), pages 711 - 715, XP029045241, ISSN: 0002-9149, DOI: 10.1016/J.AMJCARD.2014.05.060

DOI:   http://dx.doi.org/10.1016/j.amjcard.2014.05.060
   D J RADER ET AL: "The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.", JOURNAL OF CLINICAL INVESTIGATION, vol. 95, no. 3, 1 March 1995 (1995-03-01), pages 1403 - 1408, XP055215915, ISSN: 0021-9738, DOI: 10.1172/JCI117794

DOI:   http://dx.doi.org/10.1172/JCI117794
   ERIK STROES ET AL: "Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 5, no. 9, 29 August 2016 (2016-08-29), pages 1 - 11, XP055656150, ISSN: 2047-9980, DOI: 10.1161/JAHA.116.003421

DOI:   http://dx.doi.org/10.1161/JAHA.116.003421
   IOANNA GOUNI-BERTHOLD ET AL: "Lipoprotein(a): Current Perspectives", CURRENT VASCULAR PHARMACOLOGY, vol. 9, no. 6, 1 November 2011 (2011-11-01), NL, pages 682 - 692, XP055497835, ISSN: 1570-1611, DOI: 10.2174/157016111797484071

DOI:   http://dx.doi.org/10.2174/157016111797484071
   EVAN A. STEIN ET AL: "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, no. 12, 22 March 2012 (2012-03-22), pages 1108 - 1118, XP055049842, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1105803

DOI:   http://dx.doi.org/10.1056/NEJMoa1105803
by applicantUS2010166768
 US6596541
   MARCOVINA; KOSCHINSKY, AM. J. CARDIOL., vol. 82, 1998, pages 57U - 66U
   IGNATESCU ET AL., THROMB. HAEMOST, vol. 80, 1998, pages 231 - 232
   LIPPI; GUIDI, Q. J. MED, vol. 93, 2000, pages 75 - 84
   BENNET, ARCH. INTERN. MED., vol. 168, 2008, pages 598 - 608
   "The Emerging Risk Factors Collaboration", 1. AM. MED. ASSOC., vol. 302, 2009, pages 412 - 423
   LEMON-FAVA, J LIPID RES., vol. 52, 2011, pages 1181 - 1187
   PARHOFER, CURRO PHARM DES, vol. 17, 2011, pages 871 - 876
   TAYLOR, NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295
   ANGAL ET AL., MOLECULAR IMMUNOLOGY, vol. 30, 1993, pages 105
   POWELL ET AL.: "Compendium of excipients for parenteral formulations", J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311, XP009119027
   WU ET AL., J, BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432
   GOODSON, MEDICAL ' APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138
   LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
   "Simon Broome Register Group", BMJ, vol. 303, 1991, pages 893 - 896
   NEIL ET AL., BMJ, vol. 321, 2000, pages 148
   WARNICK, J. LIPID RES., vol. 19, 1978, pages 65 - 76
otherWO2011028938
 EP2756004
 EP2756004
   ENKHMAA B. ET AL: "Lipoprotein (a): impact by ethnicity and environmental and medical conditions", J LIPID RES., vol. 57, no. 7, 1 July 2016 (2016-07-01), pages 1111 - 25, XP055497837

DOI:   http://dx.doi.org/10.1194/jlr.R051904
   DUB J B ET AL: "Lipoprotein(a): more interesting than ever after 50 years", CURRENT OPINION LIPIDOLOGY, vol. 23, no. 2, 1 April 2012 (2012-04-01), pages 133 - 140, XP055264229
   GOUNI-BERTHOLD I ET AL: "Lipoprotein(a): Current Perspective", CURRENT VASCULAR PHARMACOLOGY, vol. 9, no. 6, 1 November 2011 (2011-11-01), pages 682 - 692, XP055497835

DOI:   http://dx.doi.org/10.2174/157016111797484071
   VAN WISSEN ET AL: "Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia", HEART, vol. 89, 1 January 2003 (2003-01-01), pages 893 - 896, XP055393647

DOI:   http://dx.doi.org/10.1136/heart.89.8.893
   KOSCHINSKY M.L. , BOFFA M.B.: "Lipoprotein(a): An Important Cardiovascular Risk Factor and a Clinical Conundrum", ENDOCRINOL METAB CLIN N AM, vol. 43, no. 4, 26 November 2014 (2014-11-26), pages 949 - 962, XP055407332, DOI: 10.1016/j.ecl.2014.08.002

DOI:   http://dx.doi.org/10.1016/j.ecl.2014.08.002
   IKENAGA H. ET AL: "Usefulness of Lipoprotein (a) for Predicting Progression of Non-Culprit Coronary Lesions After Acute Myocardial Infarction", CIRCULATION JOURNAL, vol. 75, no. 12, 13 September 2011 (2011-09-13), pages 2847 - 2852, XP055540050

DOI:   http://dx.doi.org/10.1253/circj.CJ-11-0365
   DANIK: "Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women", JAMA, vol. 296, no. 11, 20 September 2006 (2006-09-20), pages 1363 - 1370, XP002609986

DOI:   http://dx.doi.org/10.1001/jama.296.11.1363
   "Cholesterol Management Guide for Healthcare Practitioners", AMERICAN HEART ASSOCIATION - AHA, 2018, pages 1 - 27, XP055662885, Retrieved from the Internet
   CHRISTIE BALLANTYNE: "Clinical Lipidology. A Companion to Braunwald's Heart Disease", 2009, SAUNDER ELSEVIER, article "CHALLENGES IN LIPOPROTEIN (a) MEASUREMENT", pages: 136 - 143, XP055743471

DOI:   http://dx.doi.org/10.1016/B978-141605469-6.50015-9
   WARNICK ET AL.: "Standardization of Measurements for Cholesterol, Triglycerides, and Major Lipoporteins", LAB MED, vol. 39, no. 8, 2008, pages 481,490, XP055139701, DOI: 10.1309/6UL9RHJH1JFFU4PY

DOI:   http://dx.doi.org/10.1309/6UL9RHJH1JFFU4PY
   MARCOVINA ET AL.: "Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions", CLINICAL CHEMISTRY, vol. 49, no. 11, 2003, pages 1785 - 1796, XP055620577, DOI: 10.1373/clinchem.2003.023689

DOI:   http://dx.doi.org/10.1373/clinchem.2003.023689
   STORM C.: "Bringt die 2. Testgeneration den Durchbruch fr Lp(a)?", DIAGNOSTIK IM DIALOG, vol. 41, August 2013 (2013-08-01), pages 11 - 12, XP055575872
   PARHOFER K: "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", CURRENT PHARMACEUTICAL DESIGN, vol. 17, no. 9, 1 March 2011 (2011-03-01), pages 871 - 876, XP002688212

DOI:   http://dx.doi.org/10.2174/138161211795428777
OppositionWO2010077854
 WO2009026558
 US2010166768
 WO2015054619
 WO2013016648
   ANONYMOUS: "Aber Lp(a) ist zu hoch, was kann man da tun?", AKTUELLE MEDIZIN, 26 May 2011 (2011-05-26), pages 22 - 22, XP093168119, Retrieved from the Internet [retrieved on 20240529]
   JACQUELINE SUK DANIK , NADER RIFAI, JULIE E BURING, PAUL M RIDKER: "Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women", JAMA, vol. 296, no. 11, 20 September 2006 (2006-09-20), pages 1363 - 1370, XP002609986, ISSN: 0098-7484, DOI: 10.1001/jama.296.11.1363

DOI:   http://dx.doi.org/10.1001/jama.296.11.1363
   IOANNA GOUNI-BERTHOLD, HEINER K. BERTHOLD: "Lipoprotein(a): Current Perspectives", CURRENT VASCULAR PHARMACOLOGY, vol. 9, no. 6, 1 November 2011 (2011-11-01), NL , pages 682 - 692, XP055497835, ISSN: 1570-1611, DOI: 10.2174/157016111797484071

DOI:   http://dx.doi.org/10.2174/157016111797484071
   HIROKI IKENAGA , MASAHARU ISHIHARA, ICHIRO INOUE, TAKUJI KAWAGOE, YUJI SHIMATANI, FUMIHARU MIURA, YASUHARU NAKAMA, KAZUOKI DAI, TA: "Usefulness of Lipoprotein (a) for Predicting Progression of Non-Culprit Coronary Lesions After Acute Myocardial Infarction", CIRCULATION JOURNAL, vol. 75, no. 12, 1 January 2011 (2011-01-01), JP , pages 2847 - 2852, XP055522737, ISSN: 1346-9843, DOI: 10.1253/circj.CJ-11-0365

DOI:   http://dx.doi.org/10.1253/circj.CJ-11-0365
   VALMORE BERMDEZ , ARRIZ NAILET, APARICIO DANIEL, ROJAS EDWARD, GOTERA DANIELA, GUERRA XAVIER, CANELN ROGER, FARA JUDITH, SOR: "Lipoprotein(a): From Molecules to Therapeutics", AMERICAN JOURNAL OF THERAPEUTICS, vol. 17, no. 3, 1 May 2010 (2010-05-01), US , pages 263 - 273, XP093168194, ISSN: 1075-2765, DOI: 10.1097/MJT.0b013e3181e00bf1
   BRGE G. NORDESTGAARD, M. JOHN CHAPMAN, KAUSIK RAY, JAN BORN, FELICITA ANDREOTTI, GERALD F. WATTS, HENRY GINSBERG, PIERRE AMARENC: "Lipoprotein(a) as a cardiovascular risk factor: current status", EUROPEAN HEART JOURNAL, vol. 31, no. 23, 1 December 2010 (2010-12-01), GB , pages 2844 - 2853, XP002688211, ISSN: 0195-668X, DOI: 10.1093/EURHEARTJ/EHQ386

DOI:   http://dx.doi.org/10.1093/EURHEARTJ/EHQ386
   S VAN WISSEN, SMILDE T J, TRIP M D, DE BOO TH, KASTELEIN J J P, STALENHOEF A F H: "Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia", HEART, vol. 89, 1 January 2003 (2003-01-01), pages 893 - 896, XP055393647, DOI: 10.1136/heart.89.8.893

DOI:   http://dx.doi.org/10.1136/heart.89.8.893
   KREMPLER F, KOSTNER G M, ROSCHER A, HASLAUER F, BOLZANO K, SANDHOFER F: "Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man.", JOURNAL OF CLINICAL INVESTIGATION, vol. 71, no. 5, 1 May 1983 (1983-05-01), pages 1431 - 1441, XP093168203, ISSN: 0021-9738, DOI: 10.1172/JCI110896
   HOFMANN S L, EATON D L, BROWN M S, MCCONATHY W J, GOLDSTEIN J L, HAMMER R E: "Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice.", JOURNAL OF CLINICAL INVESTIGATION, vol. 85, no. 5, 1 May 1990 (1990-05-01), pages 1542 - 1547, XP093168217, ISSN: 0021-9738, DOI: 10.1172/JCI114602
   UTERMANN G, HOPPICHLER F, DIEPLINGER H, SEED M, THOMPSON G, BOERWINKLE E: "Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 86, no. 11, 1 June 1989 (1989-06-01), pages 4171 - 4174, XP093168265, ISSN: 0027-8424, DOI: 10.1073/pnas.86.11.4171

DOI:   http://dx.doi.org/10.1073/pnas.86.11.4171
   KRAFT H. G., LINGENHEL A., RAAL F. J., HOHENEGGER M., UTERMANN G: "Lipoprotein(a) in Homozygous Familial Hypercholesterolemia", TRANSLATIONAL SCIENCES, vol. 20, no. 2, 29 May 2024 (2024-05-29), pages 522 - 528, XP093168269, ISSN: 1079-5642, DOI: 10.1161/01.ATV.20.2.522

DOI:   http://dx.doi.org/10.1161/01.ATV.20.2.522
   PARHOFER KLAUS G: "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", CURRENT PHARMACEUTICAL DESIGN, vol. 17, no. 9, 1 March 2011 (2011-03-01), NL , pages 871 - 876, XP002688212, ISSN: 1381-6128, DOI: 10.2174/138161211795428777

DOI:   http://dx.doi.org/10.2174/138161211795428777
   LADENSON PAUL W, JENS D KRISTENSEN, E CHESTER RIDGWAY, ANDERS G OLSSON, BO CARLSSON, IRWIN KLEIN, JOHN D BAXTER, BO ANGELIN: "Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 10, 11 March 2010 (2010-03-11), pages 906 - 916, XP093168275, DOI: 10.1056/NEJMoa0905633
   SUET N. CHEN, BALLANTYNE CHRISTIE M., GOTTO ANTONIO M., TAN YANLI, WILLERSON JAMES T., MARIAN ALI J.: "A Common PCSK9Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis /NIH Author Manuscript/", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 45, no. 10, 1 May 2005 (2005-05-01), AMSTERDAM, NL, pages 1611 - 1619, XP055740331, ISSN: 0735-1097, DOI: 10.1016/j.jacc.2005.01.051

DOI:   http://dx.doi.org/10.1016/j.jacc.2005.01.051
   ZELJKO REINER, ALBERICO L CATAPANO, GUY DE BACKER, IAN GRAHAM, MARJA-RIITTA TASKINEN, OLOV WIKLUND, STEFAN AGEWALL, EDUARDO ALEGRI: "ESC/EAS Guidelines for the management of dyslipidaemias", EUROPEAN HEART JOURNAL, vol. 32, 1 January 2011 (2011-01-01), pages 1769 - 11818, XP055662895
   FRANK L J VISSEREN: "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice", EUROPEAN HEART JOURNAL, vol. 42, no. 34, 7 September 2021 (2021-09-07), GB , pages 3227 - 3337, XP093168284, ISSN: 0195-668X, DOI: 10.1093/eurheartj/ehab484

DOI:   http://dx.doi.org/10.1093/eurheartj/ehab484
   MACH: "ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk", EUROPEAN HEART JOURNAL, 31 August 2019 (2019-08-31), pages 1 - 78, XP055662916
   SWERGOLD: "REGN727/SAR236553,A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY", ACC.11, vol. 57, no. 14, 5 April 2011 (2011-04-05), pages 1 - 1, XP055662879, DOI: 10.1016/S0735-1097(11)62023-8

DOI:   http://dx.doi.org/10.1016/S0735-1097(11)62023-8
   ANONYMOUS: "These Companies Are Racing To Develop The Next Big Cholesterol Drug", BUSINESS INSIDER, 31 August 2011 (2011-08-31), pages 1 - 6, XP093168316, Retrieved from the Internet [retrieved on 20240529]
   BLACKLOW, S.C.: "Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 17, no. 4, 1 August 2007 (2007-08-01), GB , pages 419 - 426, XP022273653, ISSN: 0959-440X, DOI: 10.1016/j.sbi.2007.08.017

DOI:   http://dx.doi.org/10.1016/j.sbi.2007.08.017
   JOYCE C. Y. CHAN, DEREK E. PIPER, QIONG CAO, DONGMING LIU, CHADWICK KING, WEI WANG, JIE TANG, QIANG LIU, JARED HIGBEE, ZHEN XIA, Y: "A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 24, 16 June 2009 (2009-06-16), pages 9820 - 9825, XP002657619, ISSN: 0027-8424, DOI: 10.1073/PNAS.0903849106

DOI:   http://dx.doi.org/10.1073/PNAS.0903849106
   GARY SWERGOLD: "REGN727/SAR236553, a Fully-Human Monoclonal Antibody to Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Decreases ApoB and Non-HDL-C When Administered Intravenously to Healthy Volunteer", JOURNAL OF CLINICAL LIPIDOLOGY, vol. 5, no. 3, 1 June 2011 (2011-06-01), pages 219 - 219, XP093168326
   EVAN A. STEIN, SCOTT MELLIS, GEORGE D. YANCOPOULOS, NEIL STAHL, DOUGLAS LOGAN, WILLIAM B. SMITH, ELEANOR LISBON, MARIA GUTIERREZ, : "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, no. 12, 22 March 2012 (2012-03-22), pages 1108 - 1118, XP055049842, ISSN: 00284793, DOI: 10.1056/NEJMoa1105803

DOI:   http://dx.doi.org/10.1056/NEJMoa1105803
   STEIN EVAN A, SCOTT MEILIS, GEORGE D. YANCOPOULOS, NEIL STAHL, DOUGLAS LOGAN, WILLIAM SMITH, ELEANOR LISBON, MARIA GUTIERREZ, CHER: "Supplementary Appendix Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", NEW ENGLAND JOURNAL OF MEDICINE, 22 March 2012 (2012-03-22), pages 1 - 53, XP093168337
   LIPPI G., TARGHER G.: "Optimal therapy for reduction of lipoprotein(a)", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS., BLACKWELL SCIENTIFIC PUBLICATION, OXFORD., GB, vol. 37, no. 1, 1 February 2012 (2012-02-01), GB , pages 1 - 3, XP093193399, ISSN: 0269-4727, DOI: 10.1111/j.1365-2710.2011.01244.x

DOI:   http://dx.doi.org/10.1111/j.1365-2710.2011.01244.x
   DAVIGNON J; DUBUC G; SEIDAH N G: "The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis", CURRENT ATHEROSCLEROSIS REPORTS, SPRINGER US, NEW YORK, vol. 12, no. 5, 1 September 2010 (2010-09-01), New York, pages 308 - 315, XP009163743, ISSN: 1523-3804, DOI: 10.1007/s11883-010-0123-6

DOI:   http://dx.doi.org/10.1007/s11883-010-0123-6
   ANNA BENNET: "Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease - Large-Scale Prospective Data", JAMA INTERNAL MEDICINE, AMERICAN MEDICAL ASSOCIATION, US, vol. 168, no. 6, 24 March 2008 (2008-03-24), US , pages 598 - 608, XP009557778, ISSN: 2168-6106, DOI: 10.1001/archinte.168.6.598

DOI:   http://dx.doi.org/10.1001/archinte.168.6.598
   ANONYMOUS: "Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality", JAMA; EMERGING RISK FACTORS COLLABORATION 2009, vol. 302, no. 4, 22 July 2009 (2009-07-22), pages 412 - 423, DOI: 10.1001/jama.2009.1063
   TRGOUT DAVID-ALEXANDRE, KNIG INKE R, ERDMANN JEANETTE, MUNTEANU ALEXANDRU, BRAUND PETER S, HALL ALISTAIR S, GROSSHENNIG ANIKA, : "Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease", NATURE GENETICS, NATURE PUBLISHING GROUP US, NEW YORK, vol. 41, no. 3, 1 March 2009 (2009-03-01), New York, pages 283 - 285, XP093193406, ISSN: 1061-4036, DOI: 10.1038/ng.314

DOI:   http://dx.doi.org/10.1038/ng.314
   KAMSTRUP PIA R. ET AL. : "Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction", JAMA: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, vol. 301, no. 22, 10 June 2009 (2009-06-10), pages 2331 - 2339, XP009557779, ISSN: 0254-9077, DOI: 10.1001/jama.2009.801

DOI:   http://dx.doi.org/10.1001/jama.2009.801
   ROBERT CLARKE, JOHN F. PEDEN, JEMMA C. HOPEWELL, THEODOSIOS KYRIAKOU, ANUJ GOEL, SIMON C. HEATH, SARAH PARISH, SIMONA BARLERA, MAR: "Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease", NEW ENGLAND JOURNAL OF MEDICINE, NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, no. 26, 24 December 2009 (2009-12-24), pages 2518 - 2528, XP055023613, ISSN: 00284793, DOI: 10.1056/NEJMoa0902604

DOI:   http://dx.doi.org/10.1056/NEJMoa0902604
   DUBE ET AL.: "Lipoprotein(a) more interesting than ever after 50 years", CURRENT OPINION IN LIPIDOLOGY, vol. 23, no. 2, April 2012 (2012-04-01), pages 133 - 140, XP055264229, DOI: 10.1097/MOL.0b013e32835111d8
   TERRY A. JACOBSON: "Lipoprotein(a), Cardiovascular Disease, and Contemporary Management", MAYO CLINIC PROCEEDINGS, DOWDEN HEALTH MEDIA, INC, US, vol. 88, no. 11, 1 November 2013 (2013-11-01), US , pages 1294 - 1311, XP055740338, ISSN: 0025-6196, DOI: 10.1016/j.mayocp.2013.09.003

DOI:   http://dx.doi.org/10.1016/j.mayocp.2013.09.003
   BALLANTYNE: "Clinical lipidology : a companion to Braunwald's heart disease", 1 January 2009, SAUNDERS ELSEVIER, ISBN: 1-4160-5469-3, article MARLYS L. KOSCHINSKY, SANTICA M. MARCOVINA: "Chapter 11 - Lipoprotein(a)", pages: 130 - 143, XP009559026, DOI: 10.1016/B978-141605469-6.50015-9

DOI:   http://dx.doi.org/10.1016/B978-141605469-6.50015-9
   MARLYS L. KOSCHINSKY, BOFFA MICHAEL B.: "Lipoprotein(a): An Important Cardiovascular Risk Factor and a Clinical Conundrum", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA., W.B. SAUNDERS COMPANY, PHILADELPHIA, vol. 43, no. 4, 1 December 2014 (2014-12-01), PHILADELPHIA , pages 949 - 962, XP055407332, ISSN: 0889-8529, DOI: 10.1016/j.ecl.2014.08.002

DOI:   http://dx.doi.org/10.1016/j.ecl.2014.08.002
   SZAREK MICHAEL, BITTNER VERA A, AYLWARD PHILIP, BACCARA-DINET MARIE, BHATT DEEPAK L, DIAZ RAFAEL, FRAS ZLATKO, GOODMAN SHAUN G, HA: "Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial", EUROPEAN HEART JOURNAL, OXFORD UNIVERSITY PRESS, GB, vol. 41, no. 44, 21 November 2020 (2020-11-21), GB , pages 4245 - 4255, XP093193413, ISSN: 0195-668X, DOI: 10.1093/eurheartj/ehaa649

DOI:   http://dx.doi.org/10.1093/eurheartj/ehaa649
   ODONOGHUE MICHELLE L., FAZIO SERGIO, GIUGLIANO ROBERT P., STROES ERIK S.G., KANEVSKY ESTELLA, GOUNI-BERTHOLD IOANNA, IM KYUNGAH, : "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk : Insights From the FOURIER Trial", CIRCULATION, AMERICAN HEART ASSOCIATION, US, vol. 139, no. 12, 19 March 2019 (2019-03-19), US , pages 1483 - 1492, XP055886393, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.118.037184

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037184
   MAYA S. SAFAROVA, MARAT V. EZHOV, OLGA I. AFANASIEVA, YURIY G. MATCHIN, RUSLAN V. ATANESYAN, IRINA YU. ADAMOVA, ELENA A. UTKINA, G: "Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 1, 1 January 2013 (2013-01-01), AMSTERDAM, NL , pages 93 - 99, XP055497849, ISSN: 1567-5688, DOI: 10.1016/j.atherosclerosissup.2012.10.015

DOI:   http://dx.doi.org/10.1016/j.atherosclerosissup.2012.10.015
   KOLSKI BRIAN, TSIMIKAS SOTIRIOS: "Emerging therapeutic agents to lower lipoprotein (a) levels", CURRENT OPINION IN LIPIDOLOGY, LIPPINCOTT WILLIAMS AND WILKINS, LONDON, GB, vol. 23, no. 6, 1 December 2012 (2012-12-01), LONDON, GB , pages 560 - 568, XP009557780, ISSN: 0957-9672, DOI: 10.1097/MOL.0b013e3283598d81

DOI:   http://dx.doi.org/10.1097/MOL.0b013e3283598d81
   HOBBS HELEN, WHITE ANN: "Lipoprotein (a) : Intrigues and Insights", CURRENT OPINION IN LIPIDOLOGY, LIPPINCOTT WILLIAMS AND WILKINS, LONDON, GB, vol. 10, no. 3, 1 June 1999 (1999-06-01), LONDON, GB , pages 225 - 236, XP009557781, ISSN: 0957-9672, DOI: 10.1097/00041433-199906000-00005

DOI:   http://dx.doi.org/10.1097/00041433-199906000-00005
   D J RADER, W A MANN, W CAIN, H G KRAFT, D USHER, L A ZECH, J M HOEG, J DAVIGNON, P LUPIEN, M GROSSMAN: "The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.", JOURNAL OF CLINICAL INVESTIGATION, vol. 95, no. 3, 1 March 1995 (1995-03-01), pages 1403 - 1408, XP055215915, ISSN: 00219738, DOI: 10.1172/JCI117794

DOI:   http://dx.doi.org/10.1172/JCI117794
   ANUURAD ERDEMBILEG, BOFFA MICHAEL, KOSCHINSKY MARLYS, BERGLUND LARS: "Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease", CLINICS IN LABORATORY MEDICINE., ELSEVIER, US, vol. 26, no. 4, 1 December 2006 (2006-12-01), US , pages 751 - 772, XP009557782, ISSN: 0272-2712, DOI: 10.1016/j.cll.2006.07.002

DOI:   http://dx.doi.org/10.1016/j.cll.2006.07.002
   LAMON FAVA STEFANIA, DIFFENDERFER MARGARET, MARCOVINA SANTICA: "Lipoprotein(a) metabolism", CURRENT OPINION IN LIPIDOLOGY, WOLTERS KLUWER LIPPINCOTT WILLIAMS & WILKINS, USA, vol. 25, no. 3, 1 June 2014 (2014-06-01), USA , pages 189 - 193, XP009557783, ISSN: 1473-6535, DOI: 10.1097/MOL.0000000000000070

DOI:   http://dx.doi.org/10.1097/MOL.0000000000000070
   KNIGHT BRIAN L., PEROMBELON Y.F.NICHOLAS, SOUTAR ANNE K., WADE DAVID P., SEED MARY: "Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects", ATHEROSCLEROSIS, ELSEVIER, AMSTERDAM, NL, vol. 87, no. 2-3, 1 April 1991 (1991-04-01), AMSTERDAM, NL , pages 227 - 237, XP093193421, ISSN: 0021-9150, DOI: 10.1016/0021-9150(91)90025-X
   KONRAD SCHMIDT, ASMA NOUREEN, FLORIAN KRONENBERG, GERD UTERMANN: "Structure, function, and genetics of lipoprotein (a)", JOURNAL OF LIPID RESEARCH, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC., US, vol. 57, no. 8, 1 August 2016 (2016-08-01), US , pages 1339 - 1359, XP055502476, ISSN: 0022-2275, DOI: 10.1194/jlr.R067314

DOI:   http://dx.doi.org/10.1194/jlr.R067314
   LAMBERT GILLES, THEDREZ AURLIE, CROYAL MIKAL, RAMIN-MANGATA STPHANE, COURET DAVID, DIOTEL NICOLAS, NOBCOURT-DUPUY ESTELLE, KRE: "The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies", CLINICAL SCIENCE., BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 131, no. 4, 1 February 2017 (2017-02-01), GB , pages 261 - 268, XP093193423, ISSN: 0143-5221, DOI: 10.1042/CS20160403

DOI:   http://dx.doi.org/10.1042/CS20160403
   COLHOUN, H.M. MCKEIGUE, P.M. SMITH, G.D.: "Problems of reporting genetic associations with complex outcomes", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 361, no. 9360, 8 March 2003 (2003-03-08), AMSTERDAM, NL , pages 865 - 872, XP004783610, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(03)12715-8

DOI:   http://dx.doi.org/10.1016/S0140-6736(03)12715-8
   COHEN JONATHAN C, BOERWINKLE ERIC, MOSLEY THOMAS H, HOBBS HELEN H: " Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 354, no. 12, 23 March 2006 (2006-03-23), pages 1264 - 1272, XP093193429, DOI: 10.1056/NEJMoa054013

DOI:   http://dx.doi.org/10.1056/NEJMoa054013
   OBER CAROLE, NORD ALEX S., THOMPSON EMMA E., PAN LIN, TAN ZHENG, CUSANOVICH DARREN, SUN YING, NICOLAE RALUCA, EDELSTEIN CELINA, SC: "Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q", JOURNAL OF LIPID RESEARCH, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC., US, vol. 50, no. 5, 1 May 2009 (2009-05-01), US , pages 798 - 806, XP093193431, ISSN: 0022-2275, DOI: 10.1194/jlr.M800515-JLR200
   SCHWARTZ GREGORY G., STEG P. GABRIEL, SZAREK MICHAEL, BHATT DEEPAK L., BITTNER VERA A., DIAZ RAFAEL, EDELBERG JAY M., GOODMAN SHAU: "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 379, no. 22, 29 November 2018 (2018-11-29), US , pages 2097 - 2107, XP093080663, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1801174

DOI:   http://dx.doi.org/10.1056/NEJMoa1801174
   MARC S. SABATINE, ROBERT P. GIUGLIANO, ANTHONY C. KEECH, NARIMON HONARPOUR, STEPHEN D. WIVIOTT, SABINA A. MURPHY, JULIA F. KUDER, : "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 376, no. 18, 4 May 2017 (2017-05-04), US , pages 1713 - 1722, XP055474155, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1615664

DOI:   http://dx.doi.org/10.1056/NEJMoa1615664
   WILLEIT PETER; RIDKER PAUL M; NESTEL PAUL J; SIMES JOHN; TONKIN ANDREW M; PEDERSEN TERJE R; SCHWARTZ GREGORY G; OLSSON ANDERS G; C: "Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 392, no. 10155, 4 October 2018 (2018-10-04), AMSTERDAM, NL , pages 1311 - 1320, XP085505005, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(18)31652-0

DOI:   http://dx.doi.org/10.1016/S0140-6736(18)31652-0
   ALBERS JOHN J.; SLEE APRIL; O'BRIEN KEVIN D.; ROBINSON JENNIFER G.; KASHYAP MOTI L.; KWITEROVICH PETER O.; XU PING; MARCOVINA SANT: "Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 62, no. 17, 21 August 2013 (2013-08-21), AMSTERDAM, NL, pages 1575 - 1579, XP028754933, ISSN: 0735-1097, DOI: 10.1016/j.jacc.2013.06.051

DOI:   http://dx.doi.org/10.1016/j.jacc.2013.06.051
   ERIK STROES, GUYTON JOHN R., LEPOR NORMAN, CIVEIRA FERNANDO, GAUDET DANIEL, WATTS GERALD F., BACCARA‐DINET MARIE T., LECORPS: "Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study", JOURNAL OF THE AMERICAN HEART ASSOCIATION, JOHN WILEY & SONS, vol. 5, no. 9, 29 August 2016 (2016-08-29), pages 1 - 11, XP055656150, ISSN: 2047-9980, DOI: 10.1161/JAHA.116.003421

DOI:   http://dx.doi.org/10.1161/JAHA.116.003421
   ROMAGNUOLO ROCCO, SCIPIONE COREY A., BOFFA MICHAEL B., MARCOVINA SANTICA M., SEIDAH NABIL G., KOSCHINSKY MARLYS L.: "Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 290, no. 18, 1 May 2015 (2015-05-01), US , pages 11649 - 11662, XP093193435, ISSN: 0021-9258, DOI: 10.1074/jbc.M114.611988
   COHEN J., ET AL.: "Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Nonsense Mutations in PCSK9", NATURE GENETICS, NATURE PUBLISHING GROUP US, NEW YORK, vol. 37, no. 2, 1 February 2005 (2005-02-01), New York, pages 161 - 165, XP008102949, ISSN: 1061-4036, DOI: 10.1038/ng1509

DOI:   http://dx.doi.org/10.1038/ng1509
   DI ANGELANTONIO EMANUELE, SARWAR NADEEM, PERRY PHILIP, KAPTOGE STEPHEN, RAY KAUSIK K, THOMPSON ALEXANDER, WOOD ANGELA M, LEWINGTON: "Major Lipids, Apolipoproteins, and Risk of Vascular Disease", JAMA, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, vol. 302, no. 18, 11 November 2009 (2009-11-11), Chicago, IL, pages 1993 - 2000, XP009556379, ISSN: 0098-7484, DOI: 10.1001/jama.2009.1619

DOI:   http://dx.doi.org/10.1001/jama.2009.1619
   KAMSTRUP PIA R., BENN MARIANNE, TYBJRG-HANSEN ANNE, NORDESTGAARD BRGE G.: "Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population : The Copenhagen City Heart Study", CIRCULATION, AMERICAN HEART ASSOCIATION, US, vol. 117, no. 2, 15 January 2008 (2008-01-15), US , pages 176 - 184, XP093193441, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.107.715698

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.107.715698
   ANONYMOUS: "Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy", CLINICALTRIALS.GOV; NCT01288443, 2 September 2011 (2011-09-02), XP093193446, Retrieved from the Internet
   SWERGOLD GARY, STEPHANIE BIEDERMANN, RUMIANA RENARD, DOUG NADLER, RICHARD WU, ELEANOR A. LISBON, MARIA J. GUTIERREZ, SCOTT MELLIS: "REGN727/SAR236553, a Fully-Human Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Monoclonal Antibody: Effects on Safety and Lipid and Lipoprotein Profiles When Administered Subcutaneously", AMERICAN COLLEGE OF CARDIOLOGY ANNUAL SCIENTIFIC SESSION & EXPO 2011; APRIL 3-5, 2011, AMERICAN COLLEGE OF CARDIOLOGY, 3 April 2011 (2011-04-03) - 5 April 2011 (2011-04-05), pages 1 - 1, XP093262425
   D91 - EXCERPT FROM AMGEN'S DEFENCE RE RULE 109 REQUEST
   D92 - SECOND DECLARATION OF PROF DI ANGELANTONIO_SIGNED
   SOTIRIOS TSIMIKAS, JOSEPH L WITZTUM, ELIZABETH R MILLER, WILLIAM J SASIELA, MICHAEL SZAREK, ANDERS G OLSSON, GREGORY G SCHWARTZ: "High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial", CIRCULATION, AMERICAN HEART ASSOCIATION, vol. 110, no. 11, 14 September 2004 (2004-09-14), US , pages 1406 - 1412, XP009560086, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000141728.23033.B5

DOI:   http://dx.doi.org/10.1161/01.CIR.0000141728.23033.B5
   ANGELIN, RUDLING MATS: "Lipid lowering with thyroid hormone and thyromimetics", CURRENT OPINION IN LIPIDOLOGY, LIPPINCOTT WILLIAMS AND WILKINS, LONDON, GB, vol. 21, no. 6, 1 December 2010 (2010-12-01), LONDON, GB , pages 499 - 506, XP009560087, ISSN: 0957-9672, DOI: 10.1097/MOL.0b013e3283402e9c
   D95 - "A summary of the lipid parameters measured in the anti-PCSK9 antibody clinical trials identified in HE 100 updated (BP 79.15)", ANALYSIS OF LIPID RELATED OUTCOMES MEASURED IN CLINICAL TRIALS
   SOUTAR A K, MCCARTHY S N, SEED M, KNIGHT B L: "Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the pro664----leu mutation in the LDL receptor gene.", JOURNAL OF CLINICAL INVESTIGATION, vol. 88, no. 2, 1 August 1991 (1991-08-01), pages 483 - 492, XP093259822, ISSN: 0021-9738, DOI: 10.1172/JCI115329
   GHISELLI, G. ; GADDI, A. ; BAROZZI, G. ; CIARROCCHI, A. ; DESCOVICH, G.: "Plasma lipoprotein(a) concentration in familial hypercholesterolemic patients without coronary artery disease", METABOLISM, vol. 41, no. 8, 1 August 1992 (1992-08-01), US, pages 833 - 838, XP023032925, ISSN: 0026-0495, DOI: 10.1016/0026-0495(92)90163-5

DOI:   http://dx.doi.org/10.1016/0026-0495(92)90163-5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.